Edited by Henrik G. DohlmanAtypical chemokine receptors do not mediate chemotaxis or G protein signaling, but they recruit arrestin. They also efficiently scavenge their chemokine ligands, thereby contributing to gradient maintenance and termination. ACKR3, also known as CXCR7, binds and degrades the constitutive chemokine CXCL12, which also binds the canonical receptor CXCR4, and CXCL11, which also binds CXCR3. Here we report comprehensive mutational analysis of the ACKR3 interaction with its chemokine ligands, using 30 substitution mutants.
Atypical chemokine receptors (ACKRs)4 are chemokine receptors that do not activate G protein-dependent signaling cascades upon agonist binding; they also do not mediate chemotaxis (1). Rather, chemokine binding to ACKRs leads to rapid chemokine internalization and degradation. Therefore, ACKRs act as chemokine scavengers and play a role in chemokine gradient reshaping, maintenance, and resolution.ACKR3, also known as CXCR7, is an atypical chemokine receptor for the constitutive chemokine CXCL12 (SDF-1), which also binds CXCR4 as a cognate canonical chemokine receptor (2). The second ACKR3 ligand is the highly regulated inflammatory chemokine CXCL11 (I-TAC), which also binds the canonical receptor CXCR3. Being unable to raise G protein responses in most cell types, agonist binding to ACKR3 nevertheless induces arrestin recruitment as a signaling response (3) and rapid degradation of both CXCL12 and CXCL11 (4). ACKR3 has been identified as a potentially promising drug target (2). Given the highly divergent role and regulation of its two ligands, selective interference with their ACKR3 interaction and scavenging may be of interest, warranting better understanding of ligand engagement and scavenging.The structures of chemokine receptors are beginning to be unraveled by crystallography, and the results are in line with those reported earlier from receptor mutagenesis-based approaches (5-7). The reported chemokine receptor crystals required co-crystallization in complex with receptor antagonists. CXCR4 was the first receptor crystallized in complex with an antagonistic chemokine ligand, the virally encoded vMIP-II, which has also permitted refined modeling of the putative CXCR4-CXCL12 complex (8). Overall, these structures refine an early two-step binding model that provides a conceptual framework for the interactions of chemokines with canonical chemokine receptors (for a recent critical review of this model see Kleist et al.; Ref. 9). Following this model, initial chemokine interaction with the receptor critically depends on the receptor N terminus, and some extracellular loop residues. This is then followed by secondary interaction mainly involving the chemokine N terminus with receptor binding pocket residues; this second interaction is required for receptor activation. Of note, for CXCR4 the two-step interaction model is supported by 4 The abbreviations used are: ACKR, atypical chemokine receptor; BRET, bioluminescence resonance energy transfer; CRS1, chemokine recognition...